Extremely low frequency electromagnetic fields prevent chemotherapy induced myelotoxicity.

Electromagnetic biology and medicine · 2007 · Benefit · Insufficient evidence

← Research stream

BenefitInsufficient evidencePaper 5040

The authors report experience using the SEQEX device generating ELF-EMF to reduce myelotoxicity consequent to the ABVD protocol in patients with Hodgkin's lymphoma.

Study snapshot

PublicationElectromagnetic biology and medicine · 2007

Study typerandomized_trial

Reported directionBenefit

Evidence ratingInsufficient

Abstract

Side effects of chemo-radiotherapy reduce the quality and also the survivability of patients. The consequent fatigue and infections, related to myelodepression, act to reduce the dose-intensity of the protocol. Late side effects of chemo-radiotherapy include secondary tumours, acute myeloid leukemias and cardiotoxicity. Side effects of chemotherapy are related to oxidative stress produced by the treatment. Oxidative stress also reduces the efficacy of the treatment. Antioxidative treatment with natural (dietetic) or chemical agents has been reported to reduce the toxicity of chemo-radiotherapy and improve the efficacy of treatment. We here report our experience with SEQEX, an electromedical device that generates Extremely Low Frequency ElectroMagnetic Fields (ELF-EMF) to produce endogenic cyclotronic ionic resonance, to reduce myelotoxicity consequent to ABVD protocol in patients with Hodgkin's lymphoma.

Machine Enhanced Logic

AI evidence extraction

Structured fields below were generated from the paper’s abstract and metadata to make the evidence easier to inspect. Automated extraction may be incomplete or incorrect; verify important details against the original paper.

Study typerandomized_trial

Effect directionbenefit

PopulationPatients with Hodgkin's lymphoma receiving ABVD chemotherapy

Sample sizeNot supplied

ExposureELF

Evidence strengthInsufficientConfidence: 62% · Peer reviewed: yes

Main findings

The authors report experience using the SEQEX device generating ELF-EMF to reduce myelotoxicity consequent to the ABVD protocol in patients with Hodgkin's lymphoma.

Outcomes measured

Chemotherapy-induced myelotoxicity / myelodepression

Limitations

No quantitative results provided in the abstract
Study design details (e.g., randomization, control group) not described in the abstract
Exposure parameters (frequency, intensity, duration) not reported

View raw extracted JSON

{
  "study_type": "randomized_trial",
  "exposure": {
    "band": "ELF",
    "source": "electromedical device (SEQEX)",
    "frequency_mhz": null,
    "sar_wkg": null,
    "duration": null
  },
  "population": "Patients with Hodgkin's lymphoma receiving ABVD chemotherapy",
  "sample_size": null,
  "outcomes": [
    "Chemotherapy-induced myelotoxicity / myelodepression"
  ],
  "main_findings": "The authors report experience using the SEQEX device generating ELF-EMF to reduce myelotoxicity consequent to the ABVD protocol in patients with Hodgkin's lymphoma.",
  "effect_direction": "benefit",
  "limitations": [
    "No quantitative results provided in the abstract",
    "Study design details (e.g., randomization, control group) not described in the abstract",
    "Exposure parameters (frequency, intensity, duration) not reported"
  ],
  "evidence_strength": "insufficient",
  "confidence": 0.62,
  "peer_reviewed_likely": "yes",
  "keywords": [
    "extremely low frequency",
    "ELF-EMF",
    "SEQEX",
    "electromedical device",
    "cyclotronic ionic resonance",
    "chemotherapy",
    "ABVD",
    "Hodgkin's lymphoma",
    "myelotoxicity",
    "myelodepression",
    "oxidative stress"
  ],
  "suggested_hubs": []
}

AI can be wrong. Always verify against the paper.

AI-extracted fields are generated from the abstract and metadata and may be incomplete or incorrect. This material is for informational purposes and is not medical advice.

Identifiers and source

DOI: 10.1080/15368370701761984
PubMed: 18097813

Read the original paper →

Related papers

← Back to the Research Library